We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma

This study is ongoing, but not recruiting participants.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00082888
First Posted: May 19, 2004
Last Update Posted: October 2, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
National Cancer Institute (NCI)
Results First Submitted: November 2, 2011  
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Conditions: Anaplastic Large Cell Lymphoma
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
Nodal Marginal Zone Lymphoma
Recurrent Adult Hodgkin Lymphoma
Recurrent Adult T-Cell Leukemia/Lymphoma
Recurrent Grade 1 Follicular Lymphoma
Recurrent Grade 2 Follicular Lymphoma
Recurrent Grade 3 Follicular Lymphoma
Recurrent Mantle Cell Lymphoma
Recurrent Non-Hodgkin Lymphoma
Recurrent Small Lymphocytic Lymphoma
Splenic Marginal Zone Lymphoma
Interventions: Other: Laboratory Biomarker Analysis
Drug: Tipifarnib

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Participants were recruited from 2 medical clinics in the United States between March 2004 to November 2008.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
R115777 (Tipifarnib) 300mg twice a day for 21 days. Cycle length is 28 days. After cycle 1, may increase the dose to 400mg twice a day or 600mg twice a day at physician dicretion.

Participant Flow:   Overall Study
    R115777 (Tipifarnib)
STARTED   93 
COMPLETED   71 
NOT COMPLETED   22 
Death                2 
Adverse Event                4 
Withdrawal by Subject                9 
Alternate Treatment                1 
Other Medical Problems                2 
Still receiving treatment                4 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
R115777 (Tipifarnib) 300mg twice a day for 21 days. Cycle length is 28 days. After cycle 1, may increase the dose to 400mg twice a day or 600mg twice a day at physician dicretion.

Baseline Measures
   R115777 (Tipifarnib) 
Overall Participants Analyzed 
[Units: Participants]
 93 
Age 
[Units: Years]
Median (Full Range)
 62 
 (18 to 91) 
Sex: Female, Male 
[Units: Participants]
Count of Participants
 
Female      42  45.2% 
Male      51  54.8% 
Region of Enrollment 
[Units: Participants]
 
United States   93 
Relapsed or Refractory Lymphoma 
[Units: Participants]
 
Aggressive   42 
Indolent   15 
Uncommon   36 


  Outcome Measures

1.  Primary:   Proportion of Confirmed Response (Complete Response, Unconfirmed Complete Response, or Partial Response) During the First 6 Courses of Treatment   [ Time Frame: During the first 6 cycles of treatment ]

2.  Secondary:   Overall Survival   [ Time Frame: Up to 2 years ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  

3.  Secondary:   Time to Progression   [ Time Frame: up to 2 years ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  

4.  Secondary:   Duration of Response   [ Time Frame: up to 2 years ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  

5.  Secondary:   Toxicity   [ Time Frame: 3/26/2004 - 2/1/2011 ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Thomas E. Witzig, M.D.
Organization: Mayo Clinic
phone: 507-266-2040
e-mail: witzig@mayo.edu


Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT00082888     History of Changes
Other Study ID Numbers: NCI-2012-02849
NCI-2012-02849 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
LS038B
LS038B ( Other Identifier: Mayo Clinic )
6246 ( Other Identifier: CTEP )
P30CA015083 ( U.S. NIH Grant/Contract )
P50CA097274 ( U.S. NIH Grant/Contract )
First Submitted: May 14, 2004
First Posted: May 19, 2004
Results First Submitted: November 2, 2011
Results First Posted: December 7, 2011
Last Update Posted: October 2, 2017